Key Takeaway: TScan Therapeutics has reported its financial results for the second quarter of 2026, highlighting significant progress in its clinical trials. The company has dosed the first patient in the Phase 3 ALLOHA-2™ study, with topline results anticipated by mid-2028. Additionally, positive initial data from the Phase 1 ALLOHA™ study supports their manufacturing process, and their financial position is stable through mid-2027.
Market Sentiment Analysis
POSITIVE FACTORS
First patient dosed in Phase 3 ALLOHA-2™ study.
Topline readout expected mid-2028.
Positive initial data from Cohort C of Phase 1 ALLOHA™ study.
Cash and cash equivalents fund operations into the second quarter of 2027.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+49%
120-day peak, hindsight
Typical move
8.5%
average across 5 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
TSC-101
Phase 3 · AML
Full Press Release Details
First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass.,
Frequently Asked Questions
What is the ALLOHA-2 study?
The ALLOHA-2 study is a Phase 3 clinical trial by TScan Therapeutics.
When is the topline readout for ALLOHA-2 expected?
The topline readout for the ALLOHA-2 study is expected by mid-2028.
What positive data was shared from the ALLOHA study?
Positive initial data was shared from Cohort C of the Phase 1 ALLOHA™ study.
How long can TScan fund its operations?
TScan's cash and cash equivalents can fund operations into the second quarter of 2027.